Eli Lilly Faces Earnings Miss Amid Competitive Pressures and Market Volatility

Eli Lilly's stock dropped over 10% after missing earnings expectations, with revenue of $11.4 billion and adjusted EPS of $1.18 falling short of analyst estimates. The company cited inventory issues and acquisition-related charges as factors affecting its performance. Despite the setback, long-term investors may remain optimistic due to strong demand for its diabetes and weight loss treatments, Mounjaro and Zepbound, and the potential for future growth.